13F HOLDINGS REPORT (Amended)
VR Adviser, LLC
Quarter ended Q2 2023 · Filed May 15, 2023 · Accession 0001104659-23-060779
Total Value
$507.8M
Positions
27
Other Managers
0
Confidential Omitted
No
Holdings (27)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Tricida Inc | 89610F101 | 7,132,079 | $69.0M | 13.60% |
| 2 | Aclaris Therapeutics Inc | ACRS | 4,563,962 | $63.7M | 12.55% |
| 3 | Relmada Therapeutics Inc | RLMD | 2,270,072 | $43.1M | 8.49% |
| 4 | Travere Therapeutics Inc | TVTX | 1,711,102 | $41.5M | 8.17% |
| 5 | Cogent Biosciences Inc | COGT | 4,038,117 | $36.4M | 7.17% |
| 6 | GH Research PLC | GHRS | 3,185,573 | $31.8M | 6.26% |
| 7 | Instil Bio Inc | TIL | 5,997,657 | $27.7M | 5.46% |
| 8 | Celldex Therapeutics Inc | CLDX | 865,116 | $23.3M | 4.59% |
| 9 | Viridian Therapeutics Inc | VRDN | 1,852,919 | $21.4M | 4.22% |
| 10 | VistaGen Therapeutics Inc | VTGN | 20,697,286 | $18.2M | 3.59% |
| 11 | Marinus Pharmaceuticals Inc | 56854Q200 | 3,156,803 | $15.3M | 3.01% |
| 12 | Aadi Bioscience Inc | WHWK | 1,173,518 | $14.5M | 2.85% |
| 13 | Inozyme Pharma Inc | 45790W108 | 2,709,987 | $12.9M | 2.55% |
| 14 | Akouos Inc | 00973J101 | 2,667,119 | $12.5M | 2.46% |
| 15 | LianBio | LIANY | 5,378,341 | $11.6M | 2.29% |
| 16 | Aerovate Therapeutics Inc | 008064107 | 590,408 | $9.2M | 1.82% |
| 17 | Trevi Therapeutics Inc | TRVI | 3,050,022 | $8.6M | 1.69% |
| 18 | Chinook Therapeutics Inc | 16961L106 | 489,618 | $8.6M | 1.69% |
| 19 | Annexon Inc | ANNX | 1,928,477 | $7.3M | 1.43% |
| 20 | Savara Inc | SVRA | 4,117,530 | $6.3M | 1.23% |
| 21 | Lyra Therapeutics Inc | LYRA | 924,170 | $5.2M | 1.03% |
| 22 | Provention Bio Inc | 74374N102 | 1,118,653 | $4.5M | 0.88% |
| 23 | Altimmune Inc | ALT | 369,306 | $4.3M | 0.85% |
| 24 | aTyr Pharma Inc | ATYR | 1,398,889 | $4.0M | 0.78% |
| 25 | Affimed NV | N01045108 | 1,428,571 | $4.0M | 0.78% |
| 26 | Rallybio Corp | RLYB | 268,532 | $2.0M | 0.40% |
| 27 | Xenon Pharmaceuticals Inc | XENE | 30,000 | $913,000 | 0.18% |